TYRX Receives FDA Clearance for AIGISRx® Neuro Antibacterial Envelope
Expands Access to Proven Antibacterial Technology to Neurosurgery
Monmouth Junction, NJ. (July 23, 2013): TYRX, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market the AIGISRx Antibacterial Envelope for use with vagus nerve stimulators, which are currently used to treat seizure disorders and depression. This approval extends TYRX’s leadership in the
commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with implantable devices into the field of neurosurgery.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.